4.4 Article

The Role of Tumor Vascularity in Predicting Survival after Yttrium-90 Radio embolization for Liver Metastases

Journal

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
Volume 20, Issue 12, Pages 1564-1569

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jvir.2009.08.013

Keywords

-

Ask authors/readers for more resources

PURPOSE: It is unclear what role pretreatment tumor vascularity plays in determining outcomes after yttrium-90 radioembolization. A hypothesis was tested that radiographic vascularity of a tumor does not affect patient survival. MATERIALS AND METHODS: In this two-institution retrospective study, 137 patients with metastatic liver disease underwent (90)Y radioembolization. Primary sites were categorized as colon, neuroendocrine, and other. All patients underwent triphasic contrast-enhanced computed tomography (CT) or magnetic resonance imaging, as well as detailed hepatic angiography. Two board-certified interventional radiologists interpreted all images and evaluated them for the presence of enhancement. Median survival times, as well as 1- and 2-year survival rates, were compared between patients with hypervascular and hypovascular tumors on (i) cross-sectional imaging and GO angiography with use of the log-rank statistic (alpha = 0.05). RESULTS: On angiography, 108 patients had hypervascular tumors and 29 had hypovascular tumors. Median survival times for the two subgroups were 300 days and 261 days, respectively (P = .95). On CT, 24 patients had hypervascular tumors and 113 had hypovascular tumors. Median survival times for these subgroups were 306 days and 284 days, respectively (P = .67). Eighty-four patients' tumors that were hypovascular on CT were hypervascular on angiography. There were no statistical differences in survival between patients with hypervascular and hypovascular tumors, regardless if vascularity was defined based on CT or angiography. CONCLUSIONS: Radiographic vascular appearance of liver tumors, regardless of imaging modality, does not affect survival after radioembolization. Therefore, hypovascular tumors should not be considered contraindicated for radioembolization.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available